Synthesis and evaluation of a novel series of 2-chloro-5-((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine analogues as potential positron emission tomography imaging agents for nicotinic acetylcholine receptors

被引:28
作者
Brown, LL
Kulkarni, S
Pavlova, OA
Koren, AO
Mukhin, AG
Newman, AH
Horti, AG
机构
[1] Natl Inst Drug Abuse, Intramural Res Program, Neuroimaging Res Branch, Baltimore, MD 21224 USA
[2] Natl Inst Drug Abuse, Intramural Res Program, Med Chem Sect, Baltimore, MD 21224 USA
关键词
D O I
10.1021/jm010550n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Reportedly, 2-[F-18]fluoro-A-85380, 1, a promising radiotracer for imaging the nicotinic acetylcholine receptor (nAChR) by positron emission tomography (PET) in humans, exhibits slow penetration through the blood-brain barrier (BBB) due to its low lipophilicity. A ligand for nAChRs with greater lipophilicity than that of 1 would be potentially more favorable for PET imaging of nAChR due to its faster penetration through the BBB. Herein, a novel series of compounds has been developed based on the high affinity ligand for nAChRs, 2-chloro-5((1-methyl-2-(S)-pyrrolidinyl)methoxy)-3-(2-(4-pyridinyl)vinyl)pyridine, 3b. The in vitro binding affinities for the new series were found to be in the range of K-i = 9-331 pM. A molecular modeling study showed differences in the comformational profiles and the electronic properties of these compounds, which provides further insight into the structure-activity relationships at nAChR. Lipophilicities of the compounds 3b-6b have been found to be substantially higher than that of 1. As a result, compounds 3b-6b might exhibit a faster penetration through the BBB than the less lipophilic 1. The N-methyl derivatives 3b and 6b demonstrated very high affinities at nAChRs (Ki = 28 and 23 pM, respectively) and will be targets for development of (CH3)-C-11-labeled derivatives as radiotracers for PET imaging of nAChRs.
引用
收藏
页码:2841 / 2849
页数:9
相关论文
共 44 条
[1]   Novel 3-pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors [J].
Abreo, MA ;
Lin, NH ;
Garvey, DS ;
Gunn, DE ;
Hettinger, AM ;
Wasicak, JT ;
Pavlik, PA ;
Martin, YC ;
DonnellyRoberts, DL ;
Anderson, DJ ;
Sullivan, JP ;
Williams, M ;
Americ, SP ;
Holladay, MW .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (04) :817-825
[2]   ANTINOCICEPTIVE EFFECTS OF THE ALKALOID EPIBATIDINE - FURTHER-STUDIES ON INVOLVEMENT OF NICOTINIC RECEPTORS [J].
BADIO, B ;
SHI, D ;
GARRAFFO, HM ;
DALY, JW .
DRUG DEVELOPMENT RESEARCH, 1995, 36 (01) :46-59
[3]   STRUCTURE AND ACTIVITY OF ACETYLCHOLINE [J].
BEERS, WH ;
REICH, E .
NATURE, 1970, 228 (5275) :917-&
[4]   Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors [J].
Brejc, K ;
van Dijk, WJ ;
Klaassen, RV ;
Schuurmans, M ;
van der Oost, J ;
Smit, AB ;
Sixma, TK .
NATURE, 2001, 411 (6835) :269-276
[5]   Chapter 26. PET ligands for assessing receptor occupancy in vivo [J].
Burns, HD ;
Hamill, TG ;
Eng, WS ;
Hargreaves, R .
ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 36, 2001, 36 :267-276
[6]   A theoretical study of epibatidine [J].
Campillo, N ;
Páez, JA ;
Alkorta, I ;
Goya, P .
JOURNAL OF THE CHEMICAL SOCIETY-PERKIN TRANSACTIONS 2, 1998, (12) :2665-2669
[7]   2-[18F]F-A-85380:: a PET radioligand for α4β2 nicotinic acetylcholine receptors [J].
Chefer, SI ;
Horti, AG ;
Koren, AO ;
Gündisch, D ;
Links, JM ;
Kurian, V ;
Dannals, RF ;
Mukhin, AG ;
London, ED .
NEUROREPORT, 1999, 10 (13) :2715-2721
[8]   STRUCTURE OF THE NICOTINIC RECEPTOR ACETYLCHOLINE-BINDING SITE - IDENTIFICATION OF ACIDIC RESIDUES IN THE DELTA-SUBUNIT WITHIN 0.9-NM OF THE ALPHA-SUBUNIT-BINDING SITE DISULFIDE [J].
CZAJKOWSKI, C ;
KARLIN, A .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1995, 270 (07) :3160-3164
[9]  
Ding YS, 1996, SYNAPSE, V24, P403
[10]   Synthesis and nicotinic acetylcholine receptor in vivo binding properties of 2-fluoro-3-[2(S)-2-azetidinylmethoxy]pyridine:: A new positron emission tomography ligand for nicotinic receptors [J].
Dollé, F ;
Dolci, L ;
Valette, H ;
Hinnen, F ;
Vaufrey, F ;
Guenther, I ;
Fuseau, C ;
Coulon, C ;
Bottlaender, M ;
Crouzel, C .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (12) :2251-2259